A summary of current NKG2D-based CAR clinical trials

(young European Federation of Immunological Societies (yEFIS)) Curio, Sophie; Jonsson, Gustav; Marinović, Sonja (2021) A summary of current NKG2D-based CAR clinical trials. Immunotherapy Advances, 1 (1). ISSN 2732-4303

Preview

PDF - Published Version - article Available under License Creative Commons Attribution. Download (372kB) | Preview

Abstract

Cancer immunotherapies have significantly improved patient survival and treatment options in recent years. Nonetheless, the success of immunotherapy is limited to certain cancer types and specific subgroups of patients, making the development of new therapeutic approaches a topic of ongoing research. Chimeric antigen receptor (CAR) cells are engineered immune cells that are programmed to specifically eliminate cancer cells. Ideally, a CAR recognizes antigens that are restricted to tumor cells to avoid off-target effects. NKG2D is an activating immunoreceptor and an important player in anti-tumor immunity due to its ability to recognize tumor cells and initiate an anti- tumor immune response. Ligands for NKG2D are expressed on malignant or stressed cells and typically absent from healthy tissue, making it a promising CAR candidate. Here, we provide a summary of past and ongoing NKG2D-based CAR clinical trials and comment on potential pitfalls.

Item Type:	Article
Uncontrolled Keywords:	NKG2D ; CAR T cells ; immunotherapy ; adoptive cell transfer
Subjects:	NATURAL SCIENCES > Biology
Divisions:	Division of Molecular Medicine
Depositing User:	Sofija Konjević
Date Deposited:	28 Dec 2021 12:20
URI:	http://fulir.irb.hr/id/eprint/6824
DOI:	10.1093/immadv/ltab018

Actions (login required)

View Item